(PRWEB) May 09, 2013 The Mirena IUD lawyers at the Rottenstein Law Group are troubled by recent news reported in AdverseEvents that the U.S. Food and Drug Administration has to date received more than 47,000 adverse event reports about Mirena side effects for the Bayer-manufactured hormonal contraceptive device.* The most common side effects reported to the FDA include the expulsion of the device and the device dislocation (migration), according to a recent AdverseEvents Report. This is supported by a 2008 FDA report that mentions those alleged side effects, in addition to perforation of the uterine wall and pelvic inflammatory disease as primary potential issues.** We file Mirena lawsuits daily for those who believe their intrauterine devices have harmed them, said Rochelle Rottenstein, principal of the Rottenstein Law Group. These reports could be valuable evidence for Mirena plaintiffs during trials. Women across the United States have filed lawsuits that have been consolidated at the federal level (In re: Mirena IUD Products Liability Litigation, MDL No. 2434, U.S. District Court for the Southern District of New York) and in at least one state (In re: Application for Centralized Management of Certain Cases Involving Mirena, Morris County (N.J.) Superior Court) there has also … Continue reading →

Contributor (866) 529-2400 Propecia giveth and Propecia taketh away. Approved by the U.S. Food and Drug Administration in 1997 for the treatment of male pattern hair loss, Propecia (finasteride) is the first pill that effectively treats MPHL on the vertex and anterior mid-scalp area, according to the Merck products marketing. In clinical studies, according to Merck, 9 out of 10 guys saw results with Propecia. On the other hand, one-fifth of balding men in a clinical series referred to in the November 2012 Journal of Sexual Medicine, reported, despite drug discontinuation, persistent sexual dysfunction for [greater than or equal to] 6 years, suggesting the possibility that the dysfunction may be permanent, because it frequently lingered long after the patient went off the drug. The George Washington University experiment published in the journal tracked 54 men. All subjects were otherwise healthy young men without any baseline sexual dysfunction, medical conditions, psychiatric conditions, or use of oral prescription medications prior to taking finasteride for male pattern hair loss, reads a part of the articles abstract, which was made available by the U.S. National Institutes of Health. Sexual side effects were considered persistent if they lasted at least three months. Patient follow-ups took … Continue reading →

Chicago, IL (PRWEB) May 09, 2013 The prescription drug resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa of updated safety information on the site. The warning label for the drug was recently changed to advise that some people using the medication have reported a blood condition*. The goal of DrugRisk is to improve patient safety by sharing the latest warnings, recalls, studies and legal news related to prescription drugs. Visitors can see if others are experiencing similar side effects and if legal action is under way. Pradaxa was launched in 2010 to prevent strokes in patients with atrial fibrillation. Experts have disagreed over whether it presents dangerous risks for internal bleeding. The FDA recently advised that Pradaxa is no more dangerous than traditional blood thinner warfarin**. However, DrugRisk contains information from the Institute for Safe Medication Practices, who warned that patients suffering Pradaxa bleeding are nearly 5 times as likely to die than those with bleeding from Coumadin or warfarin. They also named anticoagulants like Pradaxa among the most dangerous drugs available***. The resource center also contains a study from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and … Continue reading →